NLTX Stock Overview
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Neoleukin Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$13.96 |
52 Week High | US$18.80 |
52 Week Low | US$8.11 |
Beta | 1.1 |
1 Month Change | 5.76% |
3 Month Change | -0.14% |
1 Year Change | 59.51% |
3 Year Change | -93.52% |
5 Year Change | -66.44% |
Change since IPO | -94.16% |
Recent News & Updates
Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?
Jul 18Here's Why We're Watching Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Situation
Mar 10Recent updates
Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?
Jul 18Here's Why We're Watching Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Situation
Mar 10We're Keeping An Eye On Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Rate
Nov 19Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Deliver On Growth Plans?
Jun 03Shareholder Returns
NLTX | US Biotechs | US Market | |
---|---|---|---|
7D | 4.5% | -2.7% | -0.8% |
1Y | 59.5% | 6.6% | 26.6% |
Rentabilidad frente al sector: NLTX superó al sector US Biotechs , que obtuvo un rendimiento del -4.2% el año pasado.
Rentabilidad vs. Mercado: NLTX superó al mercado US, que obtuvo un rendimiento del 14.1% el año pasado.
Price Volatility
NLTX volatility | |
---|---|
NLTX Average Weekly Movement | 7.7% |
Biotechs Industry Average Movement | 11.8% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: NLTXha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: NLTXLa volatilidad semanal ha pasado de 44% a 87% en el último año.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 7 | Donna Cochener-Metcalfe | https://www.neoleukin.com |
Neoleukin Therapeutics, Inc. Fundamentals Summary
NLTX fundamental statistics | |
---|---|
Market cap | US$32.80m |
Earnings (TTM) | -US$34.26m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs NLTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NLTX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$34.26m |
Earnings | -US$34.26m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -14.58 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did NLTX perform over the long term?
See historical performance and comparison